Search results
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
FOX 23 News Albany· 3 hours agoNotable data include an oral presentation on biomarker analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA®), the orally ...
Kidney Cancer Immunotherapy Response Linked to Signature Reflecting HLA, Tumor Immune Activity
GenomeWeb News· 2 days agoResearchers found an immune checkpoint blockade response signature in renal cell carcinoma that reflects tumor immune activity influenced by human leukocyte antigen features.
Get Ready for ASCO 2024 Annual Meeting | Newswise
Newswise· 1 day agoASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings a
Ipilimumab, a Pioneer Breakthrough in Cancer Treatment
Forbes· 3 days agoIn 2011, the first in a new generation of anticancer drugs called checkpoint inhibitors was...
Tumor mutations may not predict response to immuno | Newswise
Newswise· 1 day agoMay 22, 2024 – The number of mutations in the DNA of cancerous tumors may not be an indicator of how...
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
Zacks via Yahoo Finance· 23 hours agoDr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop...
Great Lakes Advisors LLC Has $1.11 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 1 day agoGreat Lakes Advisors LLC trimmed its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 50.8% during the fourth quarter, according to its most recent 13F filing with the ...
Maintenance Tx With Guselkumab for UC Meets All Endpoints
Medscape· 1 day agoGuselkumab (Tremfya, Janssen/Johnson & Johnson) was superior to placebo for maintenance therapy in...
Swiss National Bank Has $3.57 Million Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 2 days agoSwiss National Bank lowered its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 10.2% in the fourth quarter, according to its most recent 13F filing with the ...
Principal Financial Group Inc. Trims Holdings in Exelixis, Inc. (NASDAQ:EXEL)
ETF DAILY NEWS· 4 days agoPrincipal Financial Group Inc. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure ...